Ionic Liquid Technology: Enabling the Oral Delivery of Peptides
Tyler Brown
Principal Scientist, i2O Therapeutics
Oral delivery of biologics has long been a sought-after goal in the biopharmaceutical industry but achieving this goal has proved challenging. i2o Therapeutics has developed a novel ionic liquid technology to address this challenge. Ionic liquids, or liquid salts comprised of loosely coordinated cations and anions, possess unique properties and offer exciting therapeutic potential, including enabling oral peptide delivery. Ionic liquids overcome all key barriers to oral delivery, including denaturation by pH, enzymatic degradation, the mucus barrier, and the epithelial barrier. Taking advantage of their highly tunable and customizable nature, we have synthesized a library of ionic liquids from biocompatible ions and have demonstrated their capabilities in oral delivery of a variety of drug types from hydrophobic
small molecules to large monoclonal antibodies. I will provide an overview of our ionic liquid platform and its capabilities in oral peptide delivery.
Dr. Tyler Brown is Principal Scientist, and Associate Director of Technology Development at i2O Therapeutics, working toward enabling the oral delivery of biologics and beyond using ionic liquids. Dr. Brown earned his PhD in Bioengineering from Harvard University in 2019 under Dr. Samir Mitragotri. After graduating from Harvard he became a Co-Founder of i2O Therapeutics with a focus on translating drug delivery technologies into viable commercial products to directly improve the lives of patients.